ANIX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 16:00):

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases...

Stats
Today's Volume	115 775
Average Volume	122 656
Market Cap	93.79M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $-0.110 ) 2024-06-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.65
ATR14	$0.0300 (1.02%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-30	Catelani Michael	Buy	1 189	Common Stock
2024-04-09	Titterton Lewis H Jr	Buy	15 009	Common Stock
2024-03-15	Baskies Arnold M	Buy	10 000	Common Stock
2024-03-15	Kumar Amit	Buy	30 000	Common Stock
2024-01-12	Baskies Arnold M	Buy	25 000	Employee Stock Option (Right to Buy)

INSIDER POWER
61.47
Last 100 transactions
Buy: 11 627 548 \| Sell: 3 491 117

Volume Correlation

Long: -0.19 (neutral)

Short: 0.45 (neutral)

Signal:(48.856) Neutral

Anixa Biosciences Inc Correlation

10 Most Positive Correlations
REKR	0.924
BDSX	0.905
IONS	0.899
SYPR	0.894
LTRX	0.892
UTME	0.89
PEV	0.882
GYRO	0.879
WKME	0.879
SOFO	0.878

10 Most Negative Correlations
CFMS	-0.898
PAE	-0.891
VSEC	-0.89
QNST	-0.888
PWP	-0.885
COUP	-0.881
NATI	-0.881
TTD	-0.879
FCYIX	-0.879
TWNK	-0.879

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Anixa Biosciences Inc Correlation - Currency/Commodity

-0.62
( weak negative )

-0.10
( neutral )

0.00
( neutral )

-0.38
( neutral )

-0.27
( neutral )

0.63
( weak )

Anixa Biosciences Inc Financials

Annual	2023
Revenue:	$210 000
Gross Profit:	$49 000.00 (23.33 %)
EPS:	$-0.320

FY	2023
Revenue:	$210 000
Gross Profit:	$49 000.00 (23.33 %)
EPS:	$-0.320

FY	2022
Revenue:	$2.47B
Gross Profit:	$2.47B (100.00 %)
EPS:	$-0.440

FY	2021
Revenue:	$512 500
Gross Profit:	$127 498 (24.88 %)
EPS:	$-0.450

Financial Reports:

No articles found.

Anixa Biosciences Inc

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.